DelveInsight’s “Down Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Down Syndrome, historical and forecasted epidemiology as well as the Down Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Down Syndrome, offering comprehensive insights into the Down Syndrome revenue trends, prevalence, and treatment landscape. The report delves into key Down Syndrome statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Down Syndrome therapies. Additionally, we cover the landscape of Down Syndrome clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Down Syndrome treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Down Syndrome space.
To Know in detail about the Down Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Down Syndrome Market Forecast
Some of the key facts of the Down Syndrome Market Report:
-
The Down Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
Key Down Syndrome Companies: Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA, AC Immune SA, AstraZeneca, and others
-
Key Down Syndrome Therapies: AEF0217, ACI-24.060, Donepezil HCl, E2020-Donepezil hydrochloride, RG1662, Florbetaben (BAY94-9172), ACI-24.060, Benralizumab, and others
-
The Down Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Down Syndrome pipeline products will significantly revolutionize the Down Syndrome market dynamics.
-
According to the DSAGSL organization (2022), around 400,000 Americans have been diagnosed with Down syndrome, and approximately 6,000 babies are born with the condition annually in the US.
-
According to the Minnesota Health Department (2023), Down syndrome occurs in 1 in 800 to 1,000 live births and is the most prevalent genetic cause of developmental delay in the US. The department also stated that there are three types of Down syndrome: trisomy 21 (nondisjunction), which accounts for 95% of cases; translocation, which accounts for about 4%; and mosaicism, which represents around 1%.
-
The Down Syndrome epidemiology based on gender analysed that males (54.5%) are affected slightly more than females (45.5%) with Down Syndrome
-
According to Hoshi et al., the overall prevalence of Down syndrome births in Japan was 5.82 per 10,000 live births.
Down Syndrome Overview
Down syndrome is a genetic disorder caused by the presence of an extra copy of chromosome 21, also known as trisomy 21. This condition leads to developmental delays, intellectual disabilities, and characteristic physical features such as a flattened face, almond-shaped eyes, and a short neck. People with Down syndrome may also experience health issues like heart defects, hearing problems, and a higher risk of certain medical conditions. While there is no cure, early intervention, educational support, and medical care can help individuals with Down syndrome lead fulfilling lives.
Get a Free sample for the Down Syndrome Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/down-syndrome-market
Down Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Down Syndrome Epidemiology Segmentation:
The Down Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Diagnosed Prevalent Cases of Down Syndrome in the 7MM
-
Type-specific Cases of Down Syndrome in the 7MM
-
Gender-specific Cases of Down Syndrome in the 7MM
-
Age-specific Cases of Down Syndrome in the 7MM
-
Treated Cases of Down Syndrome in the 7MM
Download the report to understand which factors are driving Down Syndrome epidemiology trends @ Down Syndrome Epidemiology Forecast
Down Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Down Syndrome market or expected to get launched during the study period. The analysis covers Down Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Down Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Down Syndrome Therapies and Key Companies
-
AEF0217: Aelis Farma
-
ACI-24.060: AC Immune SA
-
Donepezil HCl: Eisai Inc.
-
E2020-Donepezil hydrochloride: Eisai Co., Ltd.
-
RG1662: Hoffmann-La Roche
-
Florbetaben (BAY94-9172): Life Molecular Imaging SA
-
ACI-24.060: AC Immune SA
-
Benralizumab: AstraZeneca
Discover more about therapies set to grab major Down Syndrome market share @ Down Syndrome Treatment Landscape
Down Syndrome Market Drivers
-
Families, advocacy groups, and healthcare organizations offer strong support networks for individuals with Down syndrome, promoting awareness, research, and inclusive policies.
-
Advances in medical care and technology have improved the early detection of Down syndrome during pregnancy, allowing for better medical management and support.
Down Syndrome Market Barriers
-
Lack of approved medication for treating Down syndrome, provide pharma companies to bring novel therapies with first mover advantage.
-
Technology advancements, such as assistive devices, communication aids, and accessible applications, offer opportunities to enhance communication and daily living skills for individuals with Down syndrome.
Scope of the Down Syndrome Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Down Syndrome Companies: Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA, AC Immune SA, AstraZeneca, and others
-
Key Down Syndrome Therapies: AEF0217, ACI-24.060, Donepezil HCl, E2020-Donepezil hydrochloride, RG1662, Florbetaben (BAY94-9172), ACI-24.060, Benralizumab, and others
-
Down Syndrome Therapeutic Assessment: Down Syndrome current marketed and Down Syndrome emerging therapies
-
Down Syndrome Market Dynamics: Down Syndrome market drivers and Down Syndrome market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Down Syndrome Unmet Needs, KOL’s views, Analyst’s views, Down Syndrome Market Access and Reimbursement
To know more about Down Syndrome companies working in the treatment market, visit @ Down Syndrome Clinical Trials and Therapeutic Assessment
Table of Contents
1. Down Syndrome Market Report Introduction
2. Executive Summary for Down Syndrome
3. SWOT analysis of Down Syndrome
4. Down Syndrome Patient Share (%) Overview at a Glance
5. Down Syndrome Market Overview at a Glance
6. Down Syndrome Disease Background and Overview
7. Down Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Down Syndrome
9. Down Syndrome Current Treatment and Medical Practices
10. Down Syndrome Unmet Needs
11. Down Syndrome Emerging Therapies
12. Down Syndrome Market Outlook
13. Country-Wise Down Syndrome Market Analysis (2019–2032)
14. Down Syndrome Market Access and Reimbursement of Therapies
15. Down Syndrome Market Drivers
16. Down Syndrome Market Barriers
17. Down Syndrome Appendix
18. Down Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA